Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18273
Country/Region: Uganda
Year: 2018
Main Partner: University Research Corporation, LLC
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $5,721,347 Additional Pipeline Funding: $1,500,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $944,373
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $246,347
Care: Pediatric Care and Support (PDCS) $345,371
Laboratory Infrastructure (HLAB) $55,700
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $428,814
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $305,606
Sexual Prevention: Other Sexual Prevention (HVOP) $840,879
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $259,115
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,161,693
Treatment: Pediatric Treatment (PDTX) $133,449
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 14
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 8
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 7
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 4
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 36
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 21
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 11
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 6
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 14
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 8
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 319
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 196
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 99
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 65
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 32
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 19
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 2
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 155
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 91
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 30
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 18
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 77
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 45
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 13
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 56
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 35
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 40
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 24
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 56
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 34
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 40
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 23
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 56
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 33
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 3
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 40
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 22
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 18
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 12
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 14
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 8
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 41
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 22
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 25
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 13
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 52
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 31
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 1,040
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 616
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 171
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 102
GEND_GBV Number of people receiving post-GBV care 2019 1,211
GEND_GBV Number of people receiving post-GBV care 2019 718
HTS_SELF 15-19, Female, Directly-Assisted 2019 64
HTS_SELF 15-19, Female, Unassisted 2019 166
HTS_SELF 20-24, Female, Directly-Assisted 2019 169
HTS_SELF 20-24, Female, Unassisted 2019 498
HTS_SELF 20-24, Male, Directly-Assisted 2019 8
HTS_SELF 20-24, Male, Unassisted 2019 8
HTS_SELF 25-29, Female, Directly-Assisted 2019 100
HTS_SELF 25-29, Female, Unassisted 2019 332
HTS_SELF 25-29, Male, Directly-Assisted 2019 8
HTS_SELF 25-29, Male, Unassisted 2019 8
HTS_SELF 30-34, Female, Directly-Assisted 2019 57
HTS_SELF 30-34, Female, Unassisted 2019 133
HTS_SELF 35-39, Female, Directly-Assisted 2019 23
HTS_SELF 35-39, Female, Unassisted 2019 67
HTS_SELF 40-49, Female, Directly-Assisted 2019 6
HTS_SELF 40-49, Female, Unassisted 2019 16
HTS_SELF FSW, Directly-Assisted 2019 83
HTS_SELF FSW, Unassisted 2019 249
HTS_SELF MSM, Directly-Assisted 2019 16
HTS_SELF MSM, Unassisted 2019 16
HTS_SELF Unassisted - Sex Partner 2019 1,662
HTS_TST <5, Unknown Sex, Negative 2019 321
HTS_TST 15-19, Female, Negative 2019 178
HTS_TST 15-19, Male, Negative 2019 57
HTS_TST 20-24, Female, Negative 2019 331
HTS_TST 20-24, Male, Negative 2019 148
HTS_TST 25-29, Female, Negative 2019 555
HTS_TST 25-29, Female, Negative 2019 6,294
HTS_TST 25-29, Female, Negative 2019 8,355
HTS_TST 25-29, Female, Negative 2019 413
HTS_TST 25-29, Female, Negative 2019 94
HTS_TST 25-29, Female, Negative 2019 3
HTS_TST 25-29, Female, Negative 2019 727
HTS_TST 25-29, Female, Negative 2019 1,200
HTS_TST 25-29, Female, Negative 2019 2,074
HTS_TST 25-29, Male, Negative 2019 452
HTS_TST 25-29, Male, Negative 2019 6,482
HTS_TST 25-29, Male, Negative 2019 273
HTS_TST 25-29, Male, Negative 2019 56
HTS_TST 25-29, Male, Negative 2019 8,667
HTS_TST 25-29, Male, Negative 2019 3
HTS_TST 25-29, Male, Negative 2019 300
HTS_TST 25-29, Male, Negative 2019 592
HTS_TST 25-29, Male, Negative 2019 791
HTS_TST 25-29, Male, Negative 2019 1,701
HTS_TST 30-34, Female, Negative 2019 131
HTS_TST 30-34, Female, Negative 2019 2,252
HTS_TST 30-34, Female, Negative 2019 3,615
HTS_TST 30-34, Female, Negative 2019 179
HTS_TST 30-34, Female, Negative 2019 112
HTS_TST 30-34, Female, Negative 2019 1
HTS_TST 30-34, Female, Negative 2019 172
HTS_TST 30-34, Female, Negative 2019 518
HTS_TST 30-34, Female, Negative 2019 494
HTS_TST 30-34, Male, Negative 2019 1,312
HTS_TST 30-34, Male, Negative 2019 350
HTS_TST 30-34, Male, Negative 2019 4,152
HTS_TST 30-34, Male, Negative 2019 183
HTS_TST 30-34, Male, Negative 2019 75
HTS_TST 30-34, Male, Negative 2019 1,155
HTS_TST 30-34, Male, Negative 2019 2
HTS_TST 30-34, Male, Negative 2019 40
HTS_TST 30-34, Male, Negative 2019 457
HTS_TST 30-34, Male, Negative 2019 527
HTS_TST 35-39, Female, Negative 2019 932
HTS_TST 35-39, Female, Negative 2019 249
HTS_TST 35-39, Female, Negative 2019 2,486
HTS_TST 35-39, Female, Negative 2019 3,753
HTS_TST 35-39, Female, Negative 2019 186
HTS_TST 35-39, Female, Negative 2019 140
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Female, Negative 2019 1
HTS_TST 35-39, Female, Negative 2019 324
HTS_TST 35-39, Female, Negative 2019 539
HTS_TST 35-39, Male, Negative 2019 1,558
HTS_TST 35-39, Male, Negative 2019 416
HTS_TST 35-39, Male, Negative 2019 4,700
HTS_TST 35-39, Male, Negative 2019 245
HTS_TST 35-39, Male, Negative 2019 227
HTS_TST 35-39, Male, Negative 2019 1,155
HTS_TST 35-39, Male, Negative 2019 2
HTS_TST 35-39, Male, Negative 2019 1
HTS_TST 35-39, Male, Negative 2019 40
HTS_TST 35-39, Male, Negative 2019 543
HTS_TST 35-39, Male, Negative 2019 710
HTS_TST 40-49, Female, Negative 2019 856
HTS_TST 40-49, Female, Negative 2019 228
HTS_TST 40-49, Female, Negative 2019 2,017
HTS_TST 40-49, Female, Negative 2019 2,528
HTS_TST 40-49, Female, Negative 2019 125
HTS_TST 40-49, Female, Negative 2019 94
HTS_TST 40-49, Female, Negative 2019 1
HTS_TST 40-49, Female, Negative 2019 251
HTS_TST 40-49, Female, Negative 2019 364
HTS_TST 40-49, Male, Negative 2019 1,973
HTS_TST 40-49, Male, Negative 2019 526
HTS_TST 40-49, Male, Negative 2019 3,809
HTS_TST 40-49, Male, Negative 2019 227
HTS_TST 40-49, Male, Negative 2019 94
HTS_TST 40-49, Male, Negative 2019 1,155
HTS_TST 40-49, Male, Negative 2019 2
HTS_TST 40-49, Male, Negative 2019 40
HTS_TST 40-49, Male, Negative 2019 685
HTS_TST 40-49, Male, Negative 2019 661
HTS_TST 50+, Female, Negative 2019 8
HTS_TST 50+, Male, Negative 2019 110
HTS_TST By Key Population: FSW, Negative 2019 961
HTS_TST By Key Population: MSM, Negative 2019 160
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 4
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 3,519
HTS_TST By Key Population: TG, Negative 2019 58
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 162,357
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 1,032
HTS_TST Service Delivery Point (Community) Index Mod: 1-9, Negative 2019 220
HTS_TST Service Delivery Point (Community) Index Mod: 10-14, Female, Negative 2019 241
HTS_TST Service Delivery Point (Community) Index Mod: 10-14, Male, Negative 2019 51
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 106
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 53
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 71
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 197
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 225
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 400
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 200
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 268
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 742
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 6
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 842
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 7,224
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 12,547
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 218
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 238
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 50
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 139
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 69
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 232
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 259
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 200
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 952
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 1,025
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 219
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 518
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 169
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 961
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 430
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 11
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 323
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 1,690
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 1,846
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 389
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 2,574
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 1,286
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 3,866
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 4,150
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 46
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,783
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 2
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 2,616
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 94
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 36
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 18
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 131
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 201
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 227
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 94
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 56
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 131
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 50
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 1,443
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 250
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 7,220
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 250
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 7,220
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2019 30
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2019 867
HTS_TST_POS <5, Unknown Sex, Positive 2019 14
HTS_TST_POS 15-19, Female, Positive 2019 14
HTS_TST_POS 15-19, Male, Positive 2019 3
HTS_TST_POS 20-24, Female, Positive 2019 24
HTS_TST_POS 20-24, Male, Positive 2019 11
HTS_TST_POS 25-29, Female, Positive 2019 97
HTS_TST_POS 25-29, Female, Positive 2019 195
HTS_TST_POS 25-29, Female, Positive 2019 215
HTS_TST_POS 25-29, Female, Positive 2019 30
HTS_TST_POS 25-29, Female, Positive 2019 13
HTS_TST_POS 25-29, Female, Positive 2019 127
HTS_TST_POS 25-29, Female, Positive 2019 63
HTS_TST_POS 25-29, Female, Positive 2019 86
HTS_TST_POS 25-29, Male, Positive 2019 79
HTS_TST_POS 25-29, Male, Positive 2019 201
HTS_TST_POS 25-29, Male, Positive 2019 20
HTS_TST_POS 25-29, Male, Positive 2019 8
HTS_TST_POS 25-29, Male, Positive 2019 39
HTS_TST_POS 25-29, Male, Positive 2019 103
HTS_TST_POS 25-29, Male, Positive 2019 42
HTS_TST_POS 25-29, Male, Positive 2019 70
HTS_TST_POS 30-34, Female, Positive 2019 24
HTS_TST_POS 30-34, Female, Positive 2019 68
HTS_TST_POS 30-34, Female, Positive 2019 168
HTS_TST_POS 30-34, Female, Positive 2019 14
HTS_TST_POS 30-34, Female, Positive 2019 14
HTS_TST_POS 30-34, Female, Positive 2019 30
HTS_TST_POS 30-34, Female, Positive 2019 27
HTS_TST_POS 30-34, Female, Positive 2019 21
HTS_TST_POS 30-34, Male, Positive 2019 55
HTS_TST_POS 30-34, Male, Positive 2019 62
HTS_TST_POS 30-34, Male, Positive 2019 127
HTS_TST_POS 30-34, Male, Positive 2019 14
HTS_TST_POS 30-34, Male, Positive 2019 9
HTS_TST_POS 30-34, Male, Positive 2019 4
HTS_TST_POS 30-34, Male, Positive 2019 80
HTS_TST_POS 30-34, Male, Positive 2019 27
HTS_TST_POS 35-39, Female, Positive 2019 39
HTS_TST_POS 35-39, Female, Positive 2019 44
HTS_TST_POS 35-39, Female, Positive 2019 76
HTS_TST_POS 35-39, Female, Positive 2019 72
HTS_TST_POS 35-39, Female, Positive 2019 14
HTS_TST_POS 35-39, Female, Positive 2019 21
HTS_TST_POS 35-39, Female, Positive 2019 55
HTS_TST_POS 35-39, Female, Positive 2019 27
HTS_TST_POS 35-39, Male, Positive 2019 66
HTS_TST_POS 35-39, Male, Positive 2019 74
HTS_TST_POS 35-39, Male, Positive 2019 146
HTS_TST_POS 35-39, Male, Positive 2019 18
HTS_TST_POS 35-39, Male, Positive 2019 31
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 94
HTS_TST_POS 35-39, Male, Positive 2019 38
HTS_TST_POS 40-49, Female, Positive 2019 36
HTS_TST_POS 40-49, Female, Positive 2019 41
HTS_TST_POS 40-49, Female, Positive 2019 61
HTS_TST_POS 40-49, Female, Positive 2019 24
HTS_TST_POS 40-49, Female, Positive 2019 9
HTS_TST_POS 40-49, Female, Positive 2019 13
HTS_TST_POS 40-49, Female, Positive 2019 43
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Male, Positive 2019 83
HTS_TST_POS 40-49, Male, Positive 2019 93
HTS_TST_POS 40-49, Male, Positive 2019 118
HTS_TST_POS 40-49, Male, Positive 2019 18
HTS_TST_POS 40-49, Male, Positive 2019 13
HTS_TST_POS 40-49, Male, Positive 2019 4
HTS_TST_POS 40-49, Male, Positive 2019 120
HTS_TST_POS 40-49, Male, Positive 2019 34
HTS_TST_POS 50+, Male, Positive 2019 9
HTS_TST_POS By Key Population: FSW, Positive 2019 425
HTS_TST_POS By Key Population: MSM, Positive 2019 72
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 1
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 636
HTS_TST_POS By Key Population: TG, Positive 2019 10
HTS_TST_POS Service Delivery Point (Community) Index Mod: 1-9, Positive 2019 11
HTS_TST_POS Service Delivery Point (Community) Index Mod: 10-14, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Community) Index Mod: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 19
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 35
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2019 40
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 17
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 31
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 36
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 190
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 331
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 24
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 41
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 45
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 27
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 35
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 35
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 79
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 119
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 127
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 54
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 53
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 29
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 31
HTS_TST_POS Service Delivery Point (Facility) VMMC: 50+, Positive 2019 4
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 1,583
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 107
KP_PREV By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 1,700
KP_PREV By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 9
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 3,399
PMTCT_ART Already on ART at beginning of current pregnancy 2019 2,384
PMTCT_ART New on ART 2019 895
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 3,279
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 41,471
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 2,765
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 514
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 3,279
PMTCT_EID Sum of Infant Age disaggregates 2019 3,279
PMTCT_STAT 25-29, Female 2019 9,124
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 1,085
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 7,818
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 221
PMTCT_STAT 30-34, Female 2019 7,051
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 837
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 6,044
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 170
PMTCT_STAT 35-39, Female 2019 2,902
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 349
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 2,481
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 72
PMTCT_STAT 40-49, Female 2019 829
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 101
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 708
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 20
PMTCT_STAT By Age (Numerator): 15-19 2019 7,879
PMTCT_STAT By Age (Numerator): 20-24 2019 13,686
PMTCT_STAT By Number of known positives: 15-19 2019 12
PMTCT_STAT By Number of known positives: 20-24 2019 72
PMTCT_STAT By Number of new negative: 15-19 2019 7,677
PMTCT_STAT By Number of new negative: 20-24 2019 13,283
PMTCT_STAT By Number of new positives: 15-19 2019 190
PMTCT_STAT By Number of new positives: 20-24 2019 331
PMTCT_STAT Number of new ANC and L&D clients 2019 41,471
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 41,471
PMTCT_STAT_den 25-29, Female 2019 9,124
PMTCT_STAT_den 30-34, Female 2019 7,051
PMTCT_STAT_den 35-39, Female 2019 2,902
PMTCT_STAT_den 40-49, Female 2019 829
PMTCT_STAT_den By Age (Denominator): <15-19 2019 7,879
PMTCT_STAT_den By Age (Denominator): 20-24 2019 13,686
PP_PREV 25-29, Female 2019 190
PP_PREV 25-29, Male 2019 334
PP_PREV 30-34, Female 2019 187
PP_PREV 30-34, Male 2019 320
PP_PREV 35-39, Female 2019 269
PP_PREV 35-39, Male 2019 476
PP_PREV 40-49, Female 2019 276
PP_PREV 40-49, Male 2019 502
PP_PREV Age/sex: 10-14 Female 2019 91
PP_PREV Age/sex: 15-19 Female 2019 631
PP_PREV Age/sex: 15-19 Male 2019 126
PP_PREV Age/sex: 20-24 Female 2019 619
PP_PREV Age/sex: 20-24 Male 2019 366
PP_PREV Age/sex: 50+ Female 2019 164
PP_PREV Age/sex: 50+ Male 2019 301
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 4,852
PP_PREV Sum of Age/Sex disaggregates 2019 2,298
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 76
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 459
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 3
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 70
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 777
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 6
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 1,382
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 9
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 8,471
TB_PREV Alternative TPT Regimen, Life-long ART, Already, Positive 2019 8
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 974
TB_PREV Alternative TPT Regimen, Life-long ART, New, Positive 2019 1
TB_PREV By Age/Sex (Numerator): <15, Female 2019 584
TB_PREV By Age/Sex (Numerator): <15, Male 2019 389
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 5,939
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 7
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 2,825
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 2
TB_PREV IPT, Life-long ART, Already, Positive 2019 254
TB_PREV IPT, Life-long ART, New, Positive 2019 38
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 9,737
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 9
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 11,455
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 10
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 9,966
TB_PREV_den Alternative TPT Regimen, Life-long ART, Already, Positive 2019 9
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 1,146
TB_PREV_den Alternative TPT Regimen, Life-long ART, New, Positive 2019 1
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 687
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 459
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 6,987
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 6
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 3,322
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 3
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 298
TB_PREV_den IPT, Life-long ART, New, Positive 2019 45
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 164
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 969
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 6
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 178
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,957
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 12
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 3,268
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 20
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 3,268
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 20
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 164
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 969
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 6
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 178
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,957
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 12
TX_CURR 25-29, Female, Positive 2019 5
TX_CURR 25-29, Female, Positive 2019 5,505
TX_CURR 25-29, Male, Positive 2019 1
TX_CURR 25-29, Male, Positive 2019 969
TX_CURR 30-34, Female, Positive 2019 7
TX_CURR 30-34, Female, Positive 2019 7,872
TX_CURR 30-34, Male, Positive 2019 2
TX_CURR 30-34, Male, Positive 2019 2,309
TX_CURR 35-39, Female, Positive 2019 6
TX_CURR 35-39, Female, Positive 2019 6,434
TX_CURR 35-39, Male, Positive 2019 2
TX_CURR 35-39, Male, Positive 2019 3,019
TX_CURR 40-49, Female, Positive 2019 8
TX_CURR 40-49, Female, Positive 2019 9,474
TX_CURR 40-49, Male, Positive 2019 7
TX_CURR 40-49, Male, Positive 2019 7,840
TX_CURR Age/Sex: <1 2019 252
TX_CURR Age/Sex: <1-9 2019 1,545
TX_CURR Age/Sex: 1-9 2019 2
TX_CURR Age/Sex: 10-14 Female 2019 1,257
TX_CURR Age/Sex: 10-14 Female 2019 1
TX_CURR Age/Sex: 10-14 Male 2019 537
TX_CURR Age/Sex: 10-14 Male 2019 1
TX_CURR Age/Sex: 15-19 Female 2019 1,303
TX_CURR Age/Sex: 15-19 Female 2019 1
TX_CURR Age/Sex: 15-19 Male 2019 222
TX_CURR Age/Sex: 20-24 Female 2019 3,860
TX_CURR Age/Sex: 20-24 Female 2019 4
TX_CURR Age/Sex: 20-24 Male 2019 335
TX_CURR Age/Sex: 50+ Female 2019 6
TX_CURR Age/Sex: 50+ Female 2019 6,933
TX_CURR Age/Sex: 50+ Male 2019 4,619
TX_CURR Age/Sex: 50+ Male 2019 4
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 64,285
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 57
TX_CURR Sum of age/sex disaggregates 2019 1,525
TX_CURR Sum of Age/Sex disaggregations 2019 1
TX_NEW 25-29, Female, Positive 2019 767
TX_NEW 25-29, Female, Positive 2019 4
TX_NEW 25-29, Male, Positive 2019 510
TX_NEW 30-34, Female, Positive 2019 334
TX_NEW 30-34, Male, Positive 2019 337
TX_NEW 35-39, Female, Positive 2019 346
TX_NEW 35-39, Male, Positive 2019 456
TX_NEW 40-49, Female, Positive 2019 235
TX_NEW 40-49, Male, Positive 2019 425
TX_NEW Breastfeeding status 2019 498
TX_NEW By Age/Sex: <1 2019 18
TX_NEW By Age/Sex: 1-9 2019 101
TX_NEW By Age/Sex: 10-14 Female 2019 96
TX_NEW By Age/Sex: 10-14 Male 2019 23
TX_NEW By Age/Sex: 15-19 Female 2019 334
TX_NEW By Age/Sex: 15-19 Male 2019 108
TX_NEW By Age/Sex: 20-24 Female 2019 619
TX_NEW By Age/Sex: 20-24 Male 2019 277
TX_NEW By Age/Sex: 50+ Female 2019 13
TX_NEW By Age/Sex: 50+ Male 2019 205
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 5,204
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 4
TX_NEW Pregnancy status 2019 498
TX_NEW Sum of Age/Sex disaggregates 2019 1,675
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 57,857
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 51
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2,315
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 318
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,156
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 158
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 31,821
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 29
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 4,796
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 4
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 15,043
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 13
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 2,250
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 2
TX_PVLS_den Denominator: Indication: Routine 2019 50,335
TX_PVLS_den Denominator: Indication: Routine 2019 45
TX_PVLS_den Denominator: Indication: Targeted 2019 7,522
TX_PVLS_den Denominator: Indication: Targeted 2019 6
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 262
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 141
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 9,025
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 8
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 8,004
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 8
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 17,432
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 16
TX_RET Numerator by Status: Breastfeeding 2019 1,704
TX_RET Numerator by Status: Breastfeeding 2019 1
TX_RET Numerator by Status: Pregnant 2019 1,704
TX_RET Numerator by Status: Pregnant 2019 1
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 19,369
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 18
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 291
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 158
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 10,029
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 9
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 8,891
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 9
TX_RET_den Denominator by Status: Breastfeeding 2019 1,891
TX_RET_den Denominator by Status: Breastfeeding 2019 2
TX_RET_den Denominator by Status: Pregnant 2019 1,891
TX_RET_den Denominator by Status: Pregnant 2019 2
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 64,285
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 57
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 3,858
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 4
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 2,572
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 2
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2019 34
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2019 17
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 39,212
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 18,643
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 1,927
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 2
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2019 130
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 515
TX_TB_den Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 2
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 2,572
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 55,926
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 50
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 1,672
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 1
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 6,430
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 6
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 257
VMMC_CIRC 30-34, Male 2019 1,200
VMMC_CIRC 35-39, Male 2019 1,200
VMMC_CIRC 40-49, Male 2019 1,200
VMMC_CIRC By Age: 10-14 2019 1,503
VMMC_CIRC By Age: 15-19 2019 7,504
VMMC_CIRC By Age: 20-24 2019 7,504
VMMC_CIRC By Age: 25-29 2019 9,002
VMMC_CIRC By Age: 50+ 2019 892
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 30,005
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 30,005
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 26,405
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 17,403
Cross Cutting Budget Categories and Known Amounts Total: $2,055,732
Key Populations: MSM and TG $61,078
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Training of health workers and community outreach workers
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $91,617
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: Gender Based Violence (GBV) $350,000
GBV Prevention
Post GBV Care
Gender: Gender Equality $109,610
Changing harmful gender norms and promoting positive gender norms
Increase gender-equitable access to income and productive resources, including education
Food and Nutrition: Policy, Tools, and Service Delivery $183,235
Adolescent Girls and Young Women (AGYW) $840,879
Condoms: Policy, Tools, and Services $244,313
Water $175,000